TissueGen Inc., developer of Elute fibre, a groundbreaking biodegradable fibre for delivery of the broadest range of therapeutic drugs, has been honoured with a prestigious R&D 100 Gold Award in the Market Disruptor Services Special Recognition category.
Elute fibre enables advanced drug delivery, nerve regeneration, and tissue engineering applications never before possible. TissueGen's Elute fibre directly replaces standard fibres in biodegradable monofilament formats and medical textiles and may significantly improve clinical outcomes by delivering therapeutic agents directly at the surgical site. Through controlled release of drugs at the site of implantation, Elute fibre enables medical devices to orchestrate the body's healing and regenerative responses, according to a press release.TissueGen Inc., developer of Elute fibre, a groundbreaking biodegradable fibre for delivery of the broadest range of therapeutic drugs, has been#
Christopher Knowles, CEO, TissueGen said, “We are honoured to receive the R&D 100 Award for Market Disruptor Services, affirmation that TissueGen's drug delivery technology enables truly groundbreaking products. Elute fibre is revolutionising how medical applications are approached and we anticipate wider adoption of Elute fibre in the year ahead by the pharmaceutical, therapeutic, and medical device industries.”
Widely recognised as the “Oscars of Invention,” the R&D 100 Awards identify and celebrate the top technology products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, and high-energy physics. The R&D 100 Awards span industry, academia, and government-sponsored research. (GK)
Fibre2Fashion News Desk – India
News
Articles
Interviews
Webinars
Events
Advertise with us
About Us
Contact Us
Privacy Policy
Terms & Conditions
Cookie Policy
